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The 2005 National Institutes of Health (NIH) Consensus Conference recommended assessment of lung
function in patients with chronic graft-versus-host disease (GVHD) by both pulmonary function tests (PFTs)
and assessment of pulmonary symptoms. We tested whether pulmonary measures were associated with
nonrelapse mortality (NRM), overall survival (OS), and patient-reported outcomes (PRO). Clinician and
patient-reported data were collected serially in a prospective, multicenter, observational study. Available PFT
data were abstracted. Cox regression models were ﬁt for outcomes using a time-varying covariate model for
lung function measures and adjusting for patient and transplantation characteristics and nonlung chronic
GVHD severity. A total of 1591 visits (496 patients) were used in this analysis. The NIH symptom-based lung
score was associated with NRM (P ¼ .02), OS (P ¼ .02), patient-reported symptoms (P < .001) and functional
status (P < .001). Worsening of NIH symptom-based lung score over time was associated with higher NRM
and lower survival. All other measures were not associated with OS or NRM; although, some were associated
with patient-reported lung symptoms. In conclusion, the NIH symptom-based lung symptom score of 0 to 3 is
associated with NRM, OS, and PRO measures in patients with chronic GVHD. Worsening of the NIH symptom-
based lung score was associated with increased mortality.
 2014 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.INTRODUCTION expected and FEV1/forced vital capacity (FVC) <.70.
Pulmonary dysfunction causes signiﬁcant morbidity and
mortality after allogeneic hematopoietic cell transplantation
(HCT). Symptoms may include shortness of breath with
exertion, cough, or wheezing. Routine screening with pul-
monary function tests (PFTs) can detect lung function ab-
normalities before they become symptomatic. Pulmonary
dysfunction is characterized as obstructive when the forced
expiratory volume in 1 second (FEV1) is less than 80% ofdgments on page 343.
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13.11.025Restrictive lung disease is based on decrease in total lung
capacity and is suggested when the FEV1 or FVC is less than
80% expected and the FEV1/FVC ratio is >.70. Some patients
have dysfunction of oxygen/carbon dioxide exchange as
measured by a decrease in the diffusing capacity of carbon
monoxide (DLCO). Multiple studies have shown that both
symptomatic and asymptomatic pulmonary complications
that occur later in the transplantation course are frequently
associated with graft-versus-host disease (GVHD) [1-8].
Bronchiolitis obliterans syndrome (BOS) is the best-deﬁned
pulmonary manifestation of chronic GVHD [9]. Bronchioli-
tis obliterans syndrome is diagnosed in approximately 6% of
all HCT recipients and in approximately 16% of patients with
chronic GVHD [10]. Factors reported to predict BOS include
chronic GVHD [2,4,10-16], use of methotrexate as GVHDTransplantation. Published by Elsevier Inc. All rights reserved.
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regimen [3,12,17,18], use of peripheral blood as the stem cell
source, low serum IgG [19], respiratory viral infection within
the ﬁrst 100 days post transplantation [20], and pulmonary
dysfunction before HCT [6]. Factors that are associated with a
poor prognosis once BOS is diagnosed include low serum IgG
[12], early onset after transplantation [11-13], and lack of
response to therapy [11,12]. However, none of these factors
has been consistently reported in the available literature,
which is likely constrained by the rarity of this diagnosis.
Restrictive pulmonary dysfunction is associated with, but
not diagnostic of, chronic GVHD. This ﬁnding is often observed
in patients with cryptogenic organizing pneumonia, previ-
ously called bronchiolitis obliterans organizing pneumonia.
Restrictive lung dysfunction can have both intrapulmonary
[21] and extrapulmonary etiologies, including subcutaneous
sclerosis of the torso [22].
Measurement of DLCO is frequently done but not associ-
ated with outcomes in patients with chronic GVHD [23]. This
measure has the lowest reproducibility and varies signiﬁ-
cantly between assessments because of imprecision in mea-
surements. Several reports have demonstrated that DLCO
often decreases after HCT, yet it can improve over time [2,3].
Data regarding the effect of noninfectious pulmonary
complications on survival have been inconsistent. Some
studies do not demonstrate any effect on survival [5,24].
Other studies clearly demonstrate a lower overall survival in
patients with noninfectious pulmonary complications [25].
Bronchiolitis obliterans syndrome has been associated with
dismal outcomes, with 44% survival at 2 years and 13% sur-
vival at 5 years [10]. Even modest progressive airﬂow
obstruction, deﬁned as an annualized decrease of at least 5%
per year, has been associated with attributable mortality
rates of 9% at 3 years, 12% at 5 years, and 18% at 10 years after
transplantation. Among patients with chronic GVHD, attrib-
utable mortality rates were even higher: 22% at 3 years, 27%
at 5 years, and 40% at 10 years [26].
In 2005, the NIH held a consensus conference to improve
methods of diagnosis and response assessment in chronic
GVHD. In this conference, standardized deﬁnitions were
recommended for BOS: (1) FEV1/FVC ratio of <.70; (2) FEV1
<75% predicted; (3) air-trapping demonstrated by residual
volume >120% predicted or high resolution computed to-
mography scan; and (4) absence of an infectious etiology [9].
A modiﬁcation to the criteria was proposed in 2010,
removing the requirement for a demonstration of air trap-
ping, but specifying that the FEV1 should be <75% predicted
or at least 10% lower as compared with pretransplantation
PFTs, along with a FEV1/slow vital capacity <.70 [10].
Using longitudinal data collected as part of a multicenter,
observational study, we tested the pulmonary measures
recommended by the 2005 Consensus Conference on
Chronic GVHD, to determine their association with non-
relapse mortality, survival, and patient-reported outcomes.
METHODS
Chronic GVHD Consortium: Description of the Study Cohort
Data are derived from the Chronic GVHD Consortium, a prospective,
multicenter, observational study. The protocol was approved by the insti-
tutional review board at each site, and all subjects provided written
informed consent. Participants were allogeneic HCT recipients at least
2 years of age with chronic GVHD requiring systemic immunosuppressive
therapy. Patients with either classic chronic and overlap syndrome were
eligible. Cases were classiﬁed as incident (enrollment less than 3 months
after chronic GVHD diagnosis) or prevalent (enrollment 3 or more months
but less than 3 years after transplantation). Participants were identiﬁed from
the population of patients receiving their follow-up care at thetransplantation centers, which is a subset of all patients who underwent
transplantation at the center. Primary disease relapse, inability to comply
with study procedures, and anticipated survival of less than 6 months were
exclusion criteria. At enrollment and every 6 months thereafter, clinicians
and patients reported standardized information summarizing chronic GVHD
organ involvement and symptoms. Incident cases had an additional
assessment time point at 3 months after enrollment. Objective medical data,
including ancillary testing and laboratory results, medical complications,
andmedication proﬁles, were abstracted through standardized chart review
after each visit.
Pulmonary Variables
Pulmonary function testing is recommended by the consensus confer-
ence, and results associated with each study visit  1 month were recorded
when available. Although PFTs were recommended at 3-month intervals,
they were not required. The NIH lung scoring system has 2 parts. One is a
clinical lung symptom score based on symptoms, which will be referred to
hereafter as NIH symptom-based lung score, with score 0 (no symptoms),
score 1 (shortness of breath with stairs), score 2 (shortness of breath on ﬂat
ground), and score 3 (shortness of breath at rest or requiring oxygen). The
secondmeasure is based on the lung function score (LFS) calculated from the
FEV1 and DLCO corrected for hemoglobin but not alveolar volume [9]. This
score will be called the NIH PFT-based lung score to distinguish it from the
symptom-based score. The FEV1 and DLCO are converted to a numeric score
as follows:>80%¼ 1; 70% to 79%¼ 2; 60% to 69%¼ 3; 50% to 59%¼ 4; 40% to
49% ¼ 5; and <40% ¼ 6. The LFS ¼ FEV1 score þ DLCO score, with a possible
range of 2 to 12, with higher numbers indicating worse dysfunction. The NIH
PFT-based Lung Score (0 to 3) is derived as follows: 0 ¼ FEV1 >80% or LFS 2;
1 ¼ FEV160% to 79% or LFS 3 to 5; 2 ¼ FEV140% to 59% or LFS 6 to 9; and 3 ¼
FEV1 39% or LFS 10 to 12. In addition, we administered a portable
spirometry test during study visits with a hand-held spirometer, which re-
cords FEV1. The average of 3 attempts was used in the analysis.
Statistical Analyses
We initially performed an unbiased approach on all the measured fac-
tors using both univariable and multivariable analysis. Analyses included
both cross sectional values and change between assessments. Results were
inconsistent when evaluated from a speciﬁc time point (such as enrollment
or 6months) or as a kinetic measurement of change over 6months (data not
shown), perhaps because of collinearity between measures. Therefore, we
pursued hypothesis-driven analyses instead.
We focused on a set of hypothesized associations between pulmonary
measures and nonrelapse mortality (NRM), overall survival (OS), and
patient-reported outcomes (PROs). The 7 measures of interest were as
follows: (1) obstructive lung disease based on PFTs, deﬁned as a FEV1/FVC
ratio of <.7 (2 levels of FEV1 were tested: <50% [severe obstructive disease]
and 50% to 80% of predicted [mild and moderate obstructive disease]);
(2) restrictive lung disease deﬁned as FVC 80% AND FEV1/FVC .7; (3) NIH
PFT-based lung score (0 to 3); (4) NIH symptom-based lung score (0 to 3);
(5) clinical diagnosis of BOS, as reported by the clinician in the provider
survey; (6) decrease in FEV1 or FVC percent predicted by 10% compared
with the ﬁrst set of PFTs tested after enrollment; and (7) worsening in NIH
symptom-based lung score by 1 point or greater compared with the ﬁrst
recorded score.
Overall survival was deﬁned from time of enrollment, with patients
censored at date of last known to be alive. Nonrelapse mortality was deﬁned
as death without prior relapse. Cox regression models were ﬁt for OS and
NRM using a time-varying covariate model for lung function measures,
adjusting for patient characteristics and chronic GVHD global severity
calculated without the lung component. Patient characteristics included
platelet count (<100K, 100K), bilirubin (2 mg/dL, >2 mg/dL), Karnofsky
performance score (<80, 80, missing), conditioning regimen (myeloa-
blative, reduced intensity/nonmyeloablative), GVHD type (overlap, classic),
and HCTcomorbidity scale without the lung component [27]. We also looked
at other covariates, although they were not adjusted because of lack of as-
sociation with OS or NRM, including: study site (Fred Hutchinson Cancer
Research Center, other), case type (incident, prevalent), time from trans-
plantation to enrollment (<12 months, 12 months), patient age at trans-
plantation (<50 years, 50 years), donor match (matched related, matched
unrelated, mismatched), donor patient gender combination (female into
male, other), and prior acute GVHD (yes, no). These covariates considered
were chosen a priori based on associations with OS or NRM in previous
studies.
In separate models limited to patients with at least 2 sets of PFTs during
the study, we compared survival of patients whose percent predicted FEV1
or FVC declined by 10% or more from the ﬁrst PFTs recorded after enrollment
using time-varying indicators compared with those with stable or improved
PFTs. We repeated this model with the FEV1 derived from the hand-held
Table 1
Characteristics of the Study Population at Enrollment (n ¼ 496)
Characteristics Category n Count (%)
Case type Incident 496 281 (57%)
Prevalent 215 (43%)
Adult or child Adult (18þ) 496 482 (97%)
Child (2-17) 14 (3%)
Patient gender Female 496 206 (42%)
Male 290 (58%)
Diagnosis Acute myeloid leukemia 496 164 (33%)
Acute lymphoblastic leukemia 63 (13%)
Chronic myeloid leukemia 27 (5%)
Chronic lymphocytic leukemia 38 (8%)
Myelodysplastic syndrome 73 (15%)
Non-Hodgkin lymphoma 70 (14%)
Hodgkin lymphoma 17 (3%)
Multiple myeloma 22 (4%)
Aplastic anemia 6 (1%)
Other 16 (3%)
Disease status Early 495 164 (33%)
Intermediate 214 (43%)
Advanced 117 (24%)
Transplant source Bone marrow 496 35 (7%)
Cord blood 23 (5%)
Peripheral blood 438 (88%)
Transplantation type Myeloablative 495 250 (51%)
Not myeloablative 245 (49%)
Total body
irradiation
No TBI 496 178 (36%)
TBI myeloablative 141 (28%)
TBI reduced intensity/
nonmyeloablative
177 (36%)
Patient CMV status Negative 493 214 (43%)
Positive 279 (57%)
Donor CMV status Negative 489 299 (61%)
Positive 190 (39%)
Donor match Matched related 495 216 (44%)
Matched unrelated 200 (40%)
Mismatched 79 (16%)
Site Fred Hutchinson Cancer
Research Center
496 227 (46%)
Mofﬁtt Cancer Center 13 (3%)
University of Minnesota 56 (11%)
Dana-Faber Cancer institute 59 (12%)
Stanford University Medical
Center
69 (14%)
Northwest Children’s Hospital 13 (3%)
Vanderbilt University
Medical Center
40 (8%)
Medical College of Wisconsin 16 (3%)
Washington University
Medical Center
3 (1%)
Prior grade acute
GVHD
Grade 0-I 496 229 (46%)
Grade II-IV 267 (54%)
NIH global severity
score
Less than mild 496 3 (1%)
Mild 41 (8%)
Moderate 261 (53%)
Severe 191 (38%)
Clinical lung
category based
on interpretation
of PFTs
Normal 259 170 (66%)
Suggestive of restrictive
dysfunction
44 (17%)
Mild to moderate obstruction 34 (13%)
Severe obstruction 11 (4%)
NIH symptom-based
lung score (0-3)
Score 0 (no symptoms) 496 375 (75%)
Score 1 (shortness of breath
with stairs)
88 (18%)
Score 2 (shortness of breath
on ﬂat ground)
30 (6%)
Score 3 (shortness of breath
at rest or requiring oxygen)
3 (1%)
NIH PFT-based lung
score (0-3)
Score 0 (FEV1 > 80% or LFS 2) 261 59 (23%)
Score 1 (FEV1 60%-79% or LFS 3-5) 141 (54%)
Score 2 (FEV1 40%-59% or LFS 6-9) 53 (20%)
Score 3 (FEV1 39% or LFS 10-12) 8 (3%)
GVHD indicates graft-versus-host disease; NIH, National Institutes of
Health; PFTs, pulmonary function tests; CMV, cytomegalovirus; FEV1, forced
expiratory volume in 1 second; LFS, lung function score; TBI, total body
irradiation.
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greater in NIH symptom-based lung score compared with the ﬁrst recorded
score.
To graphically explore whether change in FEV1 as measured by hand-
held spirometry was associated with survival status, we separately plotted
available data for patients who ultimately died versus those who were
surviving at last follow-up. Datawere separately smoothed by a penalized B-
spline curve to show the overall trend.
Agreement between FEV1 measured by hand held spirometry and PFTs
was graphically displayed with scatter plots and Bland-Altman plots [28],
and summarized by the concordance correlation coefﬁcient, using the SAS %
CCC macro [29,30]. This analysis was done only with data from patients at
Fred Hutchinson Cancer Research Center, as they were most likely to have
the PFTs and hand-held spirometry on the same day.
Utilizing all visit data, we also evaluated the association of each lung
measure with patient reported outcomes (PROs), including the Lee symp-
tom scale (lung subscale and overall scale) [31] and quality of life (SF36-
physical component score [32] and FACT-BMT [33] trial outcome index)
measures as concurrent correlates. Multivariable linear mixed models with
random patient effects were used to account for within-patient correlation.
All models were adjusted for signiﬁcant covariates, including time from
transplantation to enrollment (<12 months, 12 months), Karnofsky per-
formance score (<80, 80, missing), platelet count (100K, 100K), NIH
global severity (less than mild/mild, moderate, severe), and GVHD type
(overlap, classic). A P value of < .01 was considered signiﬁcant because of
multiple testing.
Statistical analyses were performed using SAS/STAT software, version
9.3 (SAS Institute, Inc, Cary, NC) and R version 2.15.2 (R Foundation for
Statistical Computing, Vienna, Austria).
RESULTS
Patient Characteristics
This analysis included 496 patients who were studied
during a total of 1591 visits. Approximately half the patients
were assessed at Fred Hutchinson Cancer Research Center.
Table 1 shows the characteristics of the patient population.
Median follow-up time from study entry for survivors was
19.8 months (range, .3 to 47.7). Two-year overall survival was
81%, and the median survival has not been reached in this
population. Among the 496 patients, 166 (33%) had no PFT,
134 (27%) had 1 set of PFTs, and 196 (40%) had more than 1
set of PFTs. Patients with at least 1 set of PFTs (n ¼ 330) had
similar baseline NIH symptom-based lung scores (P ¼ .38),
OS (hazard ration [HR] ¼ .9, P ¼ .71), and NRM (HR ¼ .9, P ¼
.70) compared with those with no PFTs (n ¼ 166), but they
had more severe global scores at baseline (P ¼ .003), sug-
gesting ascertainment bias in post-transplantation testing.
Of 330 patients who had at least 1 set of PFTs, repeated PFTs
were not associated with baseline NIH symptom-based lung
score (P ¼ .89) or baseline global severity (P ¼ .38). Pre-
transplantation PFT information was missing for 50 (10%) of
patients, often because patients were enrolled at a different
center thanwhere they underwent transplantation, whereas
PFTs were missing for patients at diagnosis of chronic GVHD
in 254 (51%) and at enrollment onto the study in 237 (48%) of
patients. Overall, 845 (53%) of all visits had recorded PFTs.
Pulmonary dysfunction was present at enrollment in 34%
of patients based on PFTs and 25% based on symptoms
(Table 1). Using all assessments, mild-moderate obstructive
physiology (FEV1 50% to 80%, FEV1/FVC <.70) was identiﬁed
in 137 visits (16%), and severe obstruction with FEV1 <50%
was identiﬁed in 54 visits (6%). BOSwas reported at 122 visits
from 59 patients (32 patients at enrollment) (Table 2).
Association of Cross-Sectional Pulmonary Measures with
Mortality
We tested whether cross-sectional pulmonary measures
were associated with mortality to see if any isolated assess-
ment is associated with subsequent death. The NIH
symptom-based lung score was associated with OS and NRM
Table 2
Association of Pulmonary Measures, Nonrelapse Mortality, and Overall Survival from Multivariable Time-Varying Cox Regression Models
Measure Deﬁnition N (%) Nonrelapse Mortality Overall Survival
HR 95% CI P Value HR 95% CI P Value
Lung category (n ¼ 845) Normal 520 (62%) 1.0 .53* 1.0 .55*
Suggestive of restrictive 134 (16%) 1.5 (.6-3.5) .33 1.3 (.6-2.6) .45
Mild and moderate obstructive 137 (16%) .6 (.1-1.8) .43 .7 (.2-1.7) .45
Severe obstructive 54 (6%) 1.1 (.2-3.9) .85 1.5 (.5-3.8) .47
NIH PFT-based lung score (0-3) (n ¼ 853)y Score 0 213 (25%) 1.0 .13* 1.0 .42*
Score 1 421 (49%) 2.2 (.7-9.6) .23 1.4 (.6-3.6) .41
Score 2 180 (21%) 3.9 (1.2-17.5) .04 2.0 (.8-5.4) .13
Score 3 39 (5%) 1.9 (.2-12.2) .49 2.0 (.5-7.0) .27
NIH symptom-based lung score (0-3) (n ¼ 1585) Score 0 (no symptoms) 1163 (73%) 1.0 .02* 1.0 .02*
Score 1 (shortness of breath with stairs) 304 (19%) 2.0 (1.1-3.8) .03 2.0 (1.2-3.3) .005
Score 2 (shortness of breath on ﬂat ground) 96 (6%) 2.3 (.9-5.2) .06 1.8 (.8-3.6) .12
Score 3 (shortness of breath at rest or
requiring oxygen)
22 (1%) 5.6 (1.3-17.3) .01 3.6 (.8-10.4) .04
Clinical diagnosis of bronchiolitis obliterans
syndrome (n ¼ 1583)
122 (8%) 1.7 (.7-3.5) .21 1.5 (.7-2.8) .21
HR indicates hazard ratio; CI, conﬁdence interval; NIH, National Institutes of Health; NIH-PFT, National Institutes of Health-Pulmonary Lung Function; FEV1,
forced expiratory volume in 1 second; LFS, lung function score.
Bold text indicates signifcant values to the ﬁndings.
* Overall P value.
y NIH PFT-based lung score: 0 ¼ FEV1 >80% or LFS 2; 1 ¼ FEV1 60% to 79% OR LFS 3 to 5; 2 ¼ FEV1 40% to 59% OR LFS 6 to 9; 3 ¼ FEV1  39% OR LFS 10 to 12.
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example, compared with no lung symptoms, an NIH
symptom-based lung score of 3 (shortness of breath at rest or
requiring oxygen) was associated with higher NRM (HR, 5.6;
95% conﬁdence interval [CI], 1.3 to 17.3; P ¼ .01) in the
multivariable models. Even an NIH symptom-based lung
score of 1 was associated with worse OS (HR, 2.0; 95% CI, 1.2
to 3.3; P ¼ .005). These ﬁndings were independent of Kar-
nofsky performance status, and the interaction effect was not
statistically signiﬁcant (P ¼ .34 in NRM and P ¼ .10 in OS
models), although the 2 measures had moderate correlation
with each other (Pearson correlation ¼ .34). In patients
with an NIH symptom-based lung score of 2 or 3 at enroll-
ment, median OS was 36 months and survival was 90% at 6
months, 90% at 12 months, and 82% at 18 months, suggesting
a slow, rather than rapid, rate of mortality (Figure 1). None of
the other measures, including obstructive or restrictive PFTs,Figure 1. Kaplan-Meier overall survival (left) and cumulative incidence of nonrelapsethe score based solely on the PFTs, or the clinician’s indicator
of BOS, were signiﬁcantly associated with OS or NRM.
FEV1 as assessed by hand-held spirometry and PFTs had
good agreement with a concordance correlation coefﬁcient
between the 2 measures of .74 (95% CI, .71 to 0.77) (Figure 2).
Hand-held spirometry values for FEV1 were available for
1410 visits (89%) and trends for associationwith NRM and OS
were observed but were not statistically signiﬁcant (P  .05)
at the predeﬁned cutoffs of <80% and <50%.
Association of Changes in Lung Measures with Mortality
We tested whether serial pulmonary measures were
associated with mortality to see if changes in measures are
associated with subsequent death. Using all available data
from PFTs (n ¼ 515) or hand-held spirometry (n ¼ 934) in
models where change from the ﬁrst recorded measure was
considered a time-varying covariate, we found no associationmortality (right), according to NIH symptom-based lung score at enrollment.
Figure 2. Scatter plot (left) and Bland-Altman plot (right) between hand-held spirometry and FEV1 on PFTs. On the Bland-Altman plot, the mean difference between
2 measures was centered around zero (solid line), with the 95% limits of agreement shown by dashed lines.
J. Palmer et al. / Biol Blood Marrow Transplant 20 (2014) 337e344 341between >10% change in percent predicted FEV1 and either
NRM or OS. When hand-held spirometry results were
analyzed graphically, patients who died during the obser-
vational period had a decrease in their FEV1 compared with
patients who survived (Figure 3). The spaghetti plot shows
all available data for the 2 groups with the penalized B spline
demonstrating the overall trend.
Using all available data from the NIH symptom-based lung
score (n ¼ 1089) in a model where change from the ﬁrst
recorded score was considered a time-varying covariate,
worsening at a visit by at least 1 point (n¼ 202)was associated
with both higher NRM (HR, 3.9; 95% CI,1.8 to 8.6; P¼ .001) andFigure 3. Spaghetti plot of hand-held spiromworse overall survival (HR, 2.9; 95% CI, 1.5 to 5.5; P ¼ .001)
compared with visits where patients had stable lung symptom
scores (n ¼ 759).
Association of Pulmonary Measures with Self-Reported
Outcomes
In multivariable models, the NIH symptom-based lung
score was also highly correlated with PRO including the
Lee lung symptom score, Lee summary symptom score,
SF36-physical component score, and FACT-BMT trial
outcome index (all P < .001). (Table 3) Obstructive PFTs and
bronchiolitis obliterans were associated with the Lee lungetry FEV1 according to survival status.
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ciated with any lung function measures (data not shown).
DISCUSSION
These results indicate that the NIH symptom-based lung
score is associated with OS, NRM, and PRO measures when
measured at a single time point, and worsening of the score
over time is associated with NRM and OS. The performance
of the NIH symptom-based lung score is encouraging, as it is
relatively easy to capture and is not dependent on a test that
is subject to operator error and engenders additional costs.
Its association with outcome is independent of Karnofsky
performance status and other clinical factors. Additionally,
although performance of an NIH symptom-based lung score
of 3 (shortness of breath at rest or requiring oxygen) intui-
tively is associated with worse outcomes, it is notable that
patients who have an NIH symptom-based lung score of 1
(shortness of breath with stairs) also had a worse outcome
compared with those with a score of 0.
PFT measurements at any cross-sectional time point or
worsening compared with values at the ﬁrst recorded mea-
surewere not associatedwith OS and NRM. This is surprising,
as most studies demonstrate that the rate of change in PFTs
predicts survival evenwhen single assessments do not. Chien
et al. demonstrated that even a modest reduction in FEV1
from pretransplantation to 1 year post transplantation was
associatedwith an inferior survival [26], and Dudek et al. [12]
reported that improvement or stability in PFTs was corre-
lated with improved survival, and worsening of the PFTs
correlatedwith a signiﬁcantly worse survival [12]. In the lung
transplantation literature, both severity at onset and rate of
decline were associated with OS and NRM [34]. Four factors
may have contributed to the lack of correlation between
decline in PFT parameters and OS and NRM in our study.
First, patients were followed for a relatively short period of
time, perhaps not long enough to reveal the serial declines
that would be predictive of survival. This is compounded by
the fact that the PFT parameters evaluated may ﬂuctuate up
to 8% predicted as part of normal variation, and also will be
altered in the setting of infection or cryptogenic organizing
pneumonia. Thus, these parameters are not robust in sensi-
tivity. Second, our population is limited because of the rela-
tively few PFTs obtained on the cohort; notably 33% had no
PFTs and 27% only had 1 PFT available. Thus 60% of the total
cohort could not be evaluated for serial declines. Third, there
were only a small number of patients with severe obstruc-
tion in the cohort, limiting our ability to understand the
relative impact of severe obstruction on OS and NRM. Finally,
the background mortality rate from nonpulmonary causes
may be higher in our chronic GVHD population than in
others where pulmonary dysfunction is the major life-
threatening condition. Given that our data reveal a direct
association of symptomatic lung dysfunction with OS and
NRM in patients with chronic GVHD, more consistent PFT
monitoring could be of potential beneﬁt to capture these
patients at an earlier stage of disease and potentially initiate
interventions with a greater likelihood of success.
Clinician documentation of BOS did not have a signiﬁcant
association with OS and NRM, although BOS showed some
correlation with the Lee lung symptom score. In this cohort,
BOS was identiﬁed by clinicians in only 32 (6%) patients at
enrollment and 59 (14%) patients at any time during the
study (122 visits). Although we do not have the detailed in-
formation needed to apply the older NIH criteria for diag-
nosis of BOS, if we consider PFT data alone as a surrogate for
J. Palmer et al. / Biol Blood Marrow Transplant 20 (2014) 337e344 343the diagnosis of BOS using the modiﬁed chronic GVHD
diagnostic criteria, 6% of patients had evidence of BOS at
enrollment.
Survival for patients with NIH symptom-based lung
scores worse than 1 was better than expected compared to
historic controls. This difference may be related to the pop-
ulations studied, the relatively short period of follow-up,
improvements in supportive care, or possibly exaggerated
diagnosis (due to lack of precedent PFTs and possible long-
standing lung ﬁndings that are unassociated with HCT). It
is also possible that patients with pulmonary dysfunction
have improved outcomes because of increased awareness,
although no early interventions are reported as highly
effective. Although clinicians are not always consistent in
checking PFTs, they may be more aware of potential pul-
monary dysfunction associated with chronic GVHD; there-
fore, identifying a higher proportion of patients and starting
therapy earlier in the natural history of the disease. This
hypothesis is supported by the ﬁnding that patients with
severe chronic GVHD were more likely to have PFTs done.
Missing data limited the power of our analysis. Approxi-
mately one half of visits were missing PFT results, suggesting
that despite recommendations to follow PFTs frequently in
patients with chronic GVHD, clinicians do not consistently
follow this recommendation, which has been observed in
other analyses as well [23]. Another possible explanation for
the missing PFTs is that we captured only test results that
were within 1 month of a study visit. It is possible that many
PFTs were performed outside this window. Somewhat miti-
gating the concern about loss of power due to missing PFTs is
the fact that we had hand-held spirometry data on the ma-
jority of the patients and did not ﬁnd a consistent association
of FEV1 with OS and NRM. However, hand-held spirometry
measurements in patients who died during the observation
period showed a trend for decreased volumes. Although
these data provide insight into this otherwise absent cohort,
these data would suggest that hand-held spirometry,
although useful, is not a replacement for PFTs.
Even though results from a single PFT and changes over
time did not predict OS and NRM, we believe that PFTs
should still be performed because our analyses addressed
only the prognostic signiﬁcance of PFTs, not whether they
have a role in clarifying diagnoses or guiding management of
patients with chronic GVHD. If PFTs can detect changes
before symptoms develop, then treatments can be instituted
earlier, with the hope that morbidity and mortality can be
decreased. One study suggested that a brief course of therapy
at the onset of pulmonary dysfunction may lead to improved
outcomes [35]. The question of whether BOS-directed ther-
apy can improve prognosis in patients with this diagnosis is
also being addressed in an ongoing multicenter study that
uses prednisone, ﬂuticasone, montelukast, and azithromycin
to treat patients with BOS who are within 6 months of
diagnosis (NCI: NCT01307462). This study will assess the
relative impact of early, lung-directed treatment compared
with historical controls. This study could also provide an
improved understanding of the beneﬁt of early improvement
in PFT function with treatment. Future studies that follow
serial PFTs in patients with new onset obstructive disease
would help provide insight to the questions about the
prognostic impact of PFT abnormalities in lung disease
associated with chronic GVHD.
In summary, there is strong evidence that the NIH
symptom-based lung score, either used cross-sectionally or
as a serial measure over time, is statistically associated withNRM, OS, and PRO, and should be ascertained in patients
with chronic GVHD.ACKNOWLEDGMENTS
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